Stratos Wealth Advisors LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,537 shares of the company’s stock, valued at approximately $250,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mercer Global Advisors Inc. ADV boosted its holdings in iShares U.S. Pharmaceuticals ETF by 7.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 3,837 shares of the company’s stock worth $254,000 after purchasing an additional 266 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in iShares U.S. Pharmaceuticals ETF by 3.0% during the first quarter. Janney Montgomery Scott LLC now owns 12,489 shares of the company’s stock worth $848,000 after purchasing an additional 358 shares during the last quarter. Cultivar Capital Inc. purchased a new position in iShares U.S. Pharmaceuticals ETF during the second quarter worth about $25,000. Rothschild Investment LLC purchased a new position in iShares U.S. Pharmaceuticals ETF during the second quarter worth about $26,000. Finally, Concourse Financial Group Securities Inc. boosted its holdings in iShares U.S. Pharmaceuticals ETF by 331.0% during the first quarter. Concourse Financial Group Securities Inc. now owns 543 shares of the company’s stock worth $37,000 after purchasing an additional 417 shares during the last quarter.
iShares U.S. Pharmaceuticals ETF Stock Performance
iShares U.S. Pharmaceuticals ETF stock opened at $70.96 on Wednesday. iShares U.S. Pharmaceuticals ETF has a fifty-two week low of $55.36 and a fifty-two week high of $72.94. The stock has a market cap of $716.70 million, a PE ratio of 6.49 and a beta of 0.58. The firm’s 50-day simple moving average is $71.18 and its 200 day simple moving average is $68.01.
iShares U.S. Pharmaceuticals ETF Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Stories
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Energy and Oil Stocks Explained
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- How to Choose Top Rated Stocks
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- How is Compound Interest Calculated?
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.